Akari Enterprise Value Over E B I T D A from 2010 to 2024
| AKTX Stock | USD 1.21 0.09 8.04% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (0.68) | Current Value (0.71) | Quarterly Volatility 45.32108939 |
Check Akari Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Akari Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 6.4 M, Selling General Administrative of 7.6 M or Other Operating Expenses of 18 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Akari financial statements analysis is a perfect complement when working with Akari Therapeutics Valuation or Volatility modules.
Akari | Enterprise Value Over E B I T D A |
Latest Akari Therapeutics' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Akari Therapeutics PLC over the last few years. It is Akari Therapeutics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Akari Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Akari Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (46.05) | |
| Coefficient Of Variation | (98.42) | |
| Mean Deviation | 39.98 | |
| Median | (30.18) | |
| Standard Deviation | 45.32 | |
| Sample Variance | 2,054 | |
| Range | 124 | |
| R-Value | 0.87 | |
| Mean Square Error | 520.15 | |
| R-Squared | 0.76 | |
| Significance | 0.00002 | |
| Slope | 8.86 | |
| Total Sum of Squares | 28,756 |
Akari Enterprise Value Over E B I T D A History
About Akari Therapeutics Financial Statements
Akari Therapeutics investors use historical fundamental indicators, such as Akari Therapeutics' Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Akari Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (0.68) | (0.71) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.